Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Campone, Mario"'
Autor:
Bocquet F; Data Factory & Analytics Department, Institut de Cancérologie de l'Ouest, 44805 Nantes-Angers, France.; Law and Social Change Laboratory, Faculty of Law and Political Sciences, CNRS UMR 6297, Nantes University, 44313 Nantes, France., Raimbourg J; Oncology Department, Institut de Cancérologie de l'Ouest, 44805 Nantes-Angers, France.; Center for Research in Cancerology and Immunology Nantes-Angers, INSERM UMR 1232, Nantes University and Angers University, 44035 Nantes-Angers, France., Bigot F; Oncology Department, Institut de Cancérologie de l'Ouest, 44805 Nantes-Angers, France., Simmet V; Oncology Department, Institut de Cancérologie de l'Ouest, 44805 Nantes-Angers, France., Campone M; Oncology Department, Institut de Cancérologie de l'Ouest, 44805 Nantes-Angers, France.; Center for Research in Cancerology and Immunology Nantes-Angers, INSERM UMR 1232, Nantes University and Angers University, 44035 Nantes-Angers, France., Frenel JS; Oncology Department, Institut de Cancérologie de l'Ouest, 44805 Nantes-Angers, France.; Center for Research in Cancerology and Immunology Nantes-Angers, INSERM UMR 1232, Nantes University and Angers University, 44035 Nantes-Angers, France.
Publikováno v:
International journal of environmental research and public health [Int J Environ Res Public Health] 2023 Jan 16; Vol. 20 (2). Date of Electronic Publication: 2023 Jan 16.
Autor:
Lauzanne O; Analytics Department & Data Factory, Institut de Cancérologie de l'Ouest, F-44805 Nantes-Angers, France., Frenel JS; Oncology Department, Institut de Cancérologie de l'Ouest, F-44805 Nantes-Angers, France.; Center for Research in Cancerology and Immunology Nantes-Angers, INSERM UMR 1232, Nantes University and Angers University, F-44307 Nantes-Angers, France., Baziz M; Analytics Department & Data Factory, Institut de Cancérologie de l'Ouest, F-44805 Nantes-Angers, France., Campone M; Oncology Department, Institut de Cancérologie de l'Ouest, F-44805 Nantes-Angers, France.; Center for Research in Cancerology and Immunology Nantes-Angers, INSERM UMR 1232, Nantes University and Angers University, F-44307 Nantes-Angers, France., Raimbourg J; Oncology Department, Institut de Cancérologie de l'Ouest, F-44805 Nantes-Angers, France.; Center for Research in Cancerology and Immunology Nantes-Angers, INSERM UMR 1232, Nantes University and Angers University, F-44307 Nantes-Angers, France., Bocquet F; Analytics Department & Data Factory, Institut de Cancérologie de l'Ouest, F-44805 Nantes-Angers, France.; The Law and Social Change (DCS) Laboratory, UMR CNRS 6297, F-40000 Nantes, France.
Publikováno v:
International journal of environmental research and public health [Int J Environ Res Public Health] 2022 Apr 02; Vol. 19 (7). Date of Electronic Publication: 2022 Apr 02.
Autor:
Onesti CE; Medical Oncology Department, CHU Sart Tilman Liege and Laboratory of Human Genetics, GIGA Research Institute, University of Liège, Liège, Belgium., Tagliamento M; Oncology Department, University of Genova and IRCCS Ospedale Policlinico San Martino, Genova, Italy., Curigliano G; Oncology and Hemato-Oncology, European Institute of Oncology, IRCCS and University of Milan, Milan, Italy., Harbeck N; Breast Center, Department OB&GYN and CCCLMU, LMU University Hospital, Munich, Germany., Bartsch R; Department of Medicine I, Division of Oncology, Comprehensive Cancer Center, Medical University of Vienna, Wien, Austria., Wildiers H; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium., Tjan-Heijnen V; Medical Oncology, Maastricht University Medical Center (MUMC), Maastricht, Netherlands., Martin M; Departamento de Medicina, Instituto de Investigación Sanitaria Gregorio Marañón Universidad Complutense, Madrid, Spain., Rottey S; Department of Medical Oncology, UZ Gent, Gent, Belgium., Generali D; UO Patologia Mammaria e Ricerca Traslazionale-Breast Unit, Azienda Socio-Sanitaria, Territoriale di Cremona and University of Trieste, Cremona, Italy., Campone M; Medical Oncology, Institut de Cancérologie de l'Ouest-Pays de la Loire, Saint-Herblain, France., Cristofanilli M; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL., Pusztai L; Yale Cancer Center, Yale School of Medicine, New Haven, CT., Peeters M; Oncology Department, University Hospital Antwerp (UZA), Edegem, Belgium., Berchem G; Hemato-Oncology Department, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg., Cortes J; Oncology Department, IOB Institute of Oncology, Quiron Group, Madrid, Barcelona, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Centro Cellex, Carrer de Natzaret, Barcelona, Spain., Ruhstaller T; Medical Oncology, Breast Center Eastern Switzerland, St Gallen, Switzerland.; University of Basel, St Gallen, Switzerland., Ciruelos E; Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain., Rugo HS; Breast Care Center, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA., Jerusalem G; Medical Oncology, CHU Sart Tilman Liège and University of Liège, Liège, Belgium.
Publikováno v:
JCO global oncology [JCO Glob Oncol] 2021 Feb; Vol. 7, pp. 162-172.
Autor:
Guyon N; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Saint Herblain, France.; EpiSAVMEN Network (Région Pays de la Loire), Saint Herblain, France., Garnier D; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Saint Herblain, France.; EpiSAVMEN Network (Région Pays de la Loire), Saint Herblain, France., Briand J; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Saint Herblain, France.; EpiSAVMEN Network (Région Pays de la Loire), Saint Herblain, France., Nadaradjane A; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Saint Herblain, France.; EpiSAVMEN Network (Région Pays de la Loire), Saint Herblain, France., Bougras-Cartron G; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Saint Herblain, France.; EpiSAVMEN Network (Région Pays de la Loire), Saint Herblain, France., Raimbourg J; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.; Department of Medical Oncology, Institut de Cancérologie de l'Ouest site René Gauducheau, Saint Herblain, France., Campone M; Department of Medical Oncology, Institut de Cancérologie de l'Ouest site René Gauducheau, Saint Herblain, France., Heymann D; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France., Vallette FM; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Saint Herblain, France.; EpiSAVMEN Network (Région Pays de la Loire), Saint Herblain, France.; LabEX IGO, Université de Nantes, Nantes, France., Frenel JS; CRCINA, INSERM, Université de Nantes, Nantes, France.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France.; Department of Medical Oncology, Institut de Cancérologie de l'Ouest site René Gauducheau, Saint Herblain, France., Cartron PF; CRCINA, INSERM, Université de Nantes, Nantes, France. pierre-francois.cartron@inserm.fr.; Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l'Ouest, Saint Herblain, France. pierre-francois.cartron@inserm.fr.; Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), Saint Herblain, France. pierre-francois.cartron@inserm.fr.; EpiSAVMEN Network (Région Pays de la Loire), Saint Herblain, France. pierre-francois.cartron@inserm.fr.; LabEX IGO, Université de Nantes, Nantes, France. pierre-francois.cartron@inserm.fr.
Publikováno v:
Cell death & disease [Cell Death Dis] 2020 Dec 11; Vol. 11 (12), pp. 1048. Date of Electronic Publication: 2020 Dec 11.
Autor:
Billaud A; Université d'Angers, Inserm, CRCINA, 49000 Angers, France; Institut de cancérologie de l'Ouest, Angers, France., Chevalier LM; Université d'Angers, Inserm, CRCINA, 49000 Angers, France; Institut de cancérologie de l'Ouest, Angers, France., Campone M; Université de Nantes, Inserm, CRCINA, 44000 Nantes, France; Institut de cancérologie de l'Ouest, Angers, France., Morel A; Université d'Angers, Inserm, CRCINA, 49000 Angers, France; Institut de cancérologie de l'Ouest, Angers, France. Electronic address: alain.morel@ico.unicancer.fr., Bigot F; Institut de cancérologie de l'Ouest, Angers, France.
Publikováno v:
Bulletin du cancer [Bull Cancer] 2020 Nov; Vol. 107 (11), pp. 1161-1170. Date of Electronic Publication: 2020 Oct 15.
Autor:
Onesti CE; Department of Medical Oncology, CHU de Liège, Liege, Belgium elisaonesti@gmail.com.; Laboratory of Human Genetics, GIGA Research Institute and University of Liège, Liège, Belgium., Rugo HS; Department of Medicine and Division of Oncology, University of California San Francisco, Comprehensive Cancer Center, San Francisco, California, USA., Generali D; UO Patologia Mammaria e Ricerca Traslazionale, Breast Unit, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy.; University of Trieste, Trieste, Italy., Peeters M; Oncology Department, University Hospital Antwerp (UZA), Antwerp, Belgium., Zaman K; Oncology Department, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland., Wildiers H; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium., Harbeck N; Breast Center, Dept. OB&GYN and CCLMU, Ludwig Maximilians University Hospital, Munich, Germany., Martin M; Departamento de Medicina, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain., Cristofanilli M; Feinberg School of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA., Cortes J; Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; IOB Institute of Oncology, Madrid, Spain., Tjan-Heijnen V; Medical Oncology Department, Maastricht University Medical Center (MUMC), Maastricht, The Netherlands., Hurvitz SA; Los Angeles/Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA., Berchem G; Hemato-Oncology Department, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg., Tagliamento M; Medical Oncology 2, Ospedale Policlinico San Martino, Genova, Italy., Campone M; Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Saint Herblain, France., Bartsch R; Department of Medicine I, Medical University of Vienna, Vienna, Austria., De Placido S; Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi di Napoli Federico II, Napoli, Italy., Puglisi F; Department of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy., Rottey S; Medical Oncology Department, UZ Gent, Gent, Belgium., Müller V; Ginecology Department, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Ruhstaller T; Medical Oncology Department, Breast Center of Eastern Switzerland, St Gallen, Switzerland., Machiels JP; Oncology Department, Cliniques Universitaires St. Luc, Brussels, Belgium., Conte P; Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Italy.; Division of Medical Oncology, University of Padova, Padova, Italy., Awada A; Medical Oncology Department, Institut Jules Bordet, Bruxelles, Belgium.; Medical Oncology Department, Université Libre de Bruxelles, Bruxelles, Belgium., Jerusalem G; Department of Medical Oncology, CHU de Liège, Liege, Belgium.; Université de Liège, Liege, Belgium.
Publikováno v:
ESMO open [ESMO Open] 2020 Aug; Vol. 5 (4).
Autor:
Någård M; Clinical Pharmacology and Quantitative Pharmacology, R&D Clinical Pharmacology and Safety Sciences, AstraZeneca, Gaithersburg, MD, USA., Ah-See ML; Late Stage Development, Oncology R&D, AstraZeneca, Cambridge, UK., So K; Late Stage Development, Oncology R&D, AstraZeneca, Cambridge, UK., Vermunt M; The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Thistlethwaite F; The Christie NHS Foundation Trust and University of Manchester, Manchester, UK., Labots M; Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands., Roxburgh P; Beaston West of Scotland Cancer Centre and University of Glasgow, Glasgow, UK., Ravaud A; Bordeaux University Hospital, Bordeaux, France., Campone M; ICO - Site René, Saint Herblain, France., Valkenburg-van Iersel L; Maastricht University Medical Centre, Maastricht, The Netherlands., Ottesen L; Late Stage Development, Oncology R&D, AstraZeneca, Cambridge, UK., Li Y; Clinical Pharmacology Biologics and Bioanalysis, Clinical Pharmacology and Safety Science, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA., Mugundu G; Clinical Pharmacology and Quantitative Pharmacology, R&D Clinical Pharmacology and Safety Sciences, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA. ganesh.mugundu@astrazeneca.com.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 Jul; Vol. 86 (1), pp. 97-108. Date of Electronic Publication: 2020 Jun 16.
Autor:
Jézéquel P; Unité de Bioinfomique, Institut de Cancérologie de l'Ouest-René Gauducheau, Bd J. Monod, 44805, Saint Herblain Cedex, France. pascal.jezequel@ico.unicancer.fr.; INSERM U892, IRT-UN, 8 Quai Moncousu, 44007, Nantes Cedex, France. pascal.jezequel@ico.unicancer.fr.; Service d'Oncologie Médicale, Institut de Cancérologie de l'Ouest-René Gauducheau, Bd J. Monod, 44805, Saint Herblain Cedex, France. pascal.jezequel@ico.unicancer.fr., Campone M; INSERM U892, IRT-UN, 8 Quai Moncousu, 44007, Nantes Cedex, France.; Service d'Oncologie Médicale, Institut de Cancérologie de l'Ouest-René Gauducheau, Bd J. Monod, 44805, Saint Herblain Cedex, France.
Publikováno v:
British journal of cancer [Br J Cancer] 2018 Jul; Vol. 119 (1), pp. 133-134. Date of Electronic Publication: 2018 May 14.
Autor:
Awada A; aMedical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussel, Belgium bInstitut de Cancerologie de l'Ouest, Boulevard Jacques Monod, Nantes St-Herblain Cedex cDrug Development Department, Gustave Roussy Cancer Campus, Villejuif, Cedex dUniversity Paris Sud, Orsay, France., Campone M, Varga A, Aftimos P, Frenel JS, Bahleda R, Gombos A, Bourbouloux E, Soria JC
Publikováno v:
Anti-cancer drugs [Anticancer Drugs] 2016 Apr; Vol. 27 (4), pp. 342-8.